Caresyntax, a San Francisco, CA-based provider of a vendor-neutral precision surgery platform, raised $180M in Series C funding.
The financing comprises $80M of equity and up to $100M of growth debt facility. Backers included Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance Corp.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Dennis Kogan, Caresyntax offers a vendor-neutral, precision surgery platform that delivers actionable insights to improve patient outcomes. Its proprietary software and AI platform is capturing and analyzing large volumes of video, audio, images, device data, clinical and operational data in and around the OR. The software and automation platform can be used by the care team live, during a procedure, and accessed by those outside the operating room via secured dedicated cloud and telehealth links. The platform provides meta-data insights and real-world evidence (RWE) that help surgeons and teams to improve their care, hospital administrators to use resources more efficiently, and medical device companies to advance products. It also supports insurance companies to understand and control risks, as well as enable contracts on value-based model.
Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide, delivering automation and actionable insights to hospitals, medical device companies and insurance groups.
FinsMEs
15/08/2024